Multi-center research on type 1 diabetes care and patient education in China
Studies how type 1 diabetes is managed and taught to patients across China.
Plain-language title generated from the registry record
Registry title: Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
Key facts
- Where
- Changsha, ChinaSee the site
Where in China
- Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South UniversityChangsha, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Xiangya Hospital of Central South University
- Trial code
- NCT04096794
- Record updated
- 21 April 2023
- Original description
The China Alliance for Type 1 Diabetes (CAT1D) is committed to exploring and implementing the model of graded diagnosis and treatment of type 1 diabetes and comprehensive management of outpatient service, carrying out a series of educational activities for patients, and cooperating in the development of multi-center prospective clinical research on type 1 diabetes.Read full original descriptionShow less
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
The China Alliance for Type 1 Diabetes (CAT1D) is committed to exploring and implementing the model of graded diagnosis and treatment of type 1 diabetes and comprehensive management of outpatient service, carrying out a series of educational activities for patients, and cooperating in the development of multi-center prospective clinical research on type 1 diabetes.
Inclusion: Individuals diagnosed with Type 1 Diabetes according to the 1999 World Health Organization report; Written informed consent from the patient or family representative; Individuals who own smartphone and are capable of using wechat or apps.
Exclusion: Non-t1dm patients with autoimmune polyendocrine adenopathy syndrome (APS) are the first disease; With mental disorders; Have any other condition or disease that may hamper from compliance with the protocol or complication of the trial.